Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2020 Earnings Conference Call March 11, 2021 8:00 AM ET Company Participants Joshua Reed - Chief Financial Officer Todd Brady - President & Chief Executive Officer Conference Call Participants Yigal Nochomovitz - Citigroup Louise Chen - Cantor Fitzgerald Kelly Shi - Jefferies Justin Kim - Oppenheimer Matthew Cross - Alliance Global Partners Julian Harrison - BTIG Esther Hong - Berenberg Edwin Zhang - H.C. Wainwright Prakhar Agrawal - JonesTrading Yale Jen - Laidla ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1968197 (State or othe ...

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q3 2020 Results Earnings Conference Call November 5, 2020 8:00 AM ET Company Participants Joshua Reed - Chief Financial Officer Todd Brady - President & Chief Executive Officer David McMullin - Chief Business Officer Conference Call Participants Samantha Semenkow - Citi Jennifer Kim - Cantor Fitzgerald Jackie Yan - Oppenheimer Matt Cross - Alliance Global Partners Julian Harrison - BTIG Kelly Shi - Jefferies Operator Good morning and welcome to the Aldeyra Therapeuti ...

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q2 2020 Earnings Conference Call August 6, 2020 8:00 AM ET Company Participants Joshua Reed - CFO Todd Brady - CEO, President & Director Conference Call Participants Louise Chen - Cantor Fitzgerald & Co. Justin Kim - Oppenheimer Operator Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics Second Quarter 2020 Financial Results Conference Call. [Operator Instructions]. I would now like to introduce the company's Chief Financial Offi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1968197 (State or other jur ...

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) COVID-19 Development Update Conference Call May 19, 2020 8:10 AM ET Company Participants Joshua Reed – Chief Financial Officer Todd Brady – President and Chief Executive Officer Adam Brockman – Director-Non-Clinical Development Conference Call Participants Louise Chen – Cantor Justin Kim – Oppenheimer Yigal Nochomovitz – Citigroup Yale Jen – Laidlaw & Company Esther Hong – Janney Matthew Cross – JonesTrading Operator Ladies and gentlemen, thank you for standing by an ...

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q1 2020 Results Earnings Conference Call May 7, 2020 8:00 AM ET Company Participants Joshua Reed - Chief Financial Officer Dr. Todd Brady - President and CEO David McMullin - Chief Commercial Officer Conference Call Participants Samantha Semenkow - Citi Carvey Leung - Cantor Esther Hong - Janney Matthew Cross - Jones Trading Operator Good morning. And welcome to the Aldeyra Therapeutics First Quarter 2020 Financial Results Conference Call. After the speaker’ remarks, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1968197 (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 20-1968197 (State or other jurisdiction ...